ANTXR2 and neoplasm: CMG2 was demonstrated to induce endothelial proliferation in human umbilical vein endothelial cells (HUVECs) and tumor vasculature [20], and thus was long discussed as an option for anti-angiogenic tumor therapy [28,29,30,31].